Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at Royal Bank Of Canada

by · The Cerbat Gem

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price target lifted by analysts at Royal Bank Of Canada from $95.00 to $100.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 15.83% from the company’s current price.

EW has been the topic of several other research reports. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Canaccord Genuity Group set a $89.00 price objective on shares of Edwards Lifesciences in a report on Friday. Oppenheimer cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. National Bankshares set a $92.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. Finally, BTIG Research reissued a “buy” rating and issued a $103.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.83.

Read Our Latest Report on EW

Edwards Lifesciences Trading Up 0.6%

Shares of NYSE EW opened at $86.34 on Friday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.40. The business has a 50-day moving average price of $80.75 and a two-hundred day moving average price of $78.68. The firm has a market capitalization of $50.10 billion, a PE ratio of 37.31, a PEG ratio of 3.72 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Econ Financial Services Corp acquired a new stake in Edwards Lifesciences during the 2nd quarter worth $889,000. Randolph Co Inc bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at about $301,000. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $1,760,000. Arkadios Wealth Advisors bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $300,000. Finally, OMERS ADMINISTRATION Corp boosted its stake in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Stories